TNFSF10 and cancer: Reports indicate that TRAIL induces minimal toxicity in normal tissues compared to cancer cells and as a result, TRAIL has been investigated in clinical trials either by itself or in combination with other drugs.54, 67, 68 Monoclonal antibodies, including mapatumumab, lexatumumab, conatumumab, tigatuzumab, and DAB4, that are agonistic to death receptors are currently in clinical trials for different solid and nonsolid malignancies.54, 67, 68 PRFA and NRFA polymer‐mediated delivery of a plasmid expressing the TRAIL protein resulted in death in a modest number of cancer cells.